Completed PHASE1 INTERVENTIONAL NCT01093508

Single-dose Safety Study of APD916 in Healthy Volunteers

Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects

Sponsor: Arena Pharmaceuticals

Conditions Narcolepsy With or Without Cataplexy

Interventions APD916

Updated 6 times since 2017 Last updated: Nov 1, 2010 Started: Mar 31, 2010 Primary completion: Apr 30, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01093508, this PHASE1 trial focuses on Narcolepsy With or Without Cataplexy and remains completed. Sponsored by Arena Pharmaceuticals, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arena Pharmaceuticals

Data source: Arena Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States